We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against the other best vaccine stocks to buy now.
What Will Trump’s Tariffs Mean for the Pharma Industry?
On February 24, CNBC reported that President Trump declared that sweeping US tariffs on imports from Mexico and Canada “will go forward” in a statement before the expiry of their month-long delay on their implementation. When asked about the postponed tariffs at a White House press conference, President Trump said:
“The tariffs are going forward on time, on schedule.”
He claimed that foreign nations have been taking advantage of the US in “just about everything,” reiterating his plans to impose “reciprocal tariffs.”
“So the tariffs will go forward, yes, and we’re going to make up a lot of territory,” Trump said.
On February 21, Jared Holz, Mizuho Securities America’s healthcare sector strategist, appeared on CNBC to talk about these tariffs and the ways they could affect the US pharmaceutical sector. Although he was unclear about the exact intention behind these tariffs, he said that he did not consider the pharmaceutical industry to be all that special with respect to other verticals, including technology and industrials, such that President Trump would intend to enlarge its presence in the US.
To him, the tariffs are not just about the generics or branded but are rather more about how the biotech or pharmaceutical industry fits into the grander plans around scaling up domestic manufacturing. Most biotech and pharma companies have a significant presence in the US. However, questions of whether they will hire more people in the US compared to Europe or Asia and whether they will bring back more business to America still stand without answers.
READ ALSO: 10 Best Performing Pharma Stocks So Far in 2025 and 10 Oversold Pharma Stocks to Buy According to Analysts.
Tariffs and On-Shore Capacity in the US
Although Holz was unclear about the answers to such questions, he did say that anything coming out of Europe or China would obviously be fair game. The pharmaceutical companies would say that the Inflation Reduction Act (IRA) as part of the Biden administration is incredibly crippling, and the business that needs to be tied up to make the earnings based on that is very challenging for the sector. Adding Trump’s tariffs to the list would complicate the sector possibly more than others, with the tariffs acting as a “third strike” against the US pharma sector.
Delving deeper into the topic, Holz said that building up manufacturing capacities and facilities from scratch is not as easy as it sounds and requires multiple years to reach a point where companies can produce at a high rate. Therefore, he is unclear about the impact of tariffs on the production capacity and on-shoring of pharma companies.
We recently discussed what Trump’s tariffs could mean for the healthcare industry and looked at another analyst’s perspective on the topic in a recently published article on 12 Most Oversold Healthcare Stocks to Buy Now. Here is an excerpt from the article:
“Since more and more companies in the US are looking towards China for deals regarding the next promising molecule, whether in the obesity or cancer space, the impact of tariffs on this ongoing trend has become a subject of significant discussion in the healthcare industry. On February 7, Carlo Rizzuto, Versant Ventures managing director, appeared on CNBC’s ‘Fast Money’ to discuss the impact of tariffs on healthcare. Rizzuto believed that there are two ways in which tariffs could impact the industry. The first would be products innovated in China and brought over to the US or other markets. To understand how the tariffs would affect such trade processes, the industry would have to see how the tariffs are actually structured in the market.
Secondly and more tangibly, China is a massive center for contract research and manufacturing for the US healthcare industry. Therefore, anything that increases that cost is likely to make the market conditions more challenging. The healthcare industry is already under pressure in terms of investor sentiment, and an increase in cost is not going to help its functioning.”
Our Methodology
We sifted through stock screeners, online rankings, and ETFs to compile a list of 20 vaccine stocks. We then selected the top 10 most popular stocks among elite hedge funds as of Q4 2024. We sourced the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of hedge fund sentiment.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A research scientist in a laboratory holding a vial of a biotechnology drug.
Vaxcyte, Inc. (NASDAQ:PCVX)
Number of Hedge Fund Holders: 50
Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage vaccine innovation company that develops high-fidelity vaccines. It continues to develop broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. It re-engineers the creation of highly complex vaccines through advanced chemistry and modern synthetic techniques.
Vaxcyte, Inc. (NASDAQ:PCVX) remains well-positioned to maintain continued positive momentum across its PCV (pneumococcal conjugate vaccine) franchise. Apart from this franchise, its lead clinical candidate is VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) to prevent invasive pneumococcal disease. The vaccine holds significant potential to become a best-in-class PCV in a $7 billion global market expected to reach nearly $13 billion by 2027. The vaccine has received FDA Breakthrough Therapy designation for preventing invasive pneumococcal disease in adults.
Baron Health Care Fund stated the following regarding Vaxcyte, Inc. (NASDAQ:PCVX) in its Q3 2024 investor letter:
“We purchased Vaxcyte, Inc. (NASDAQ:PCVX), a biopharmaceutical company with a next-generation vaccine platform. Vaxcyte recently showed data suggesting that their pneumococcal vaccine is better than the current vaccines on the market today. Pneumococcal vaccines are one of the largest vaccine categories today, with approximately $8 billion in worldwide sales. The vaccines are recommended for children under 5 or adults over 65 to prevent pneumococcal infection. The incumbents’ technology has hit a ceiling where their vaccines require too much protein carrier, which causes immune interference and lowered response to the pneumococcal antigen. As Pfizer and Merck have tried to add more serotypes to their vaccines, they’ve lost efficacy on some of the historically relevant serotypes. Vaxcyte’s platform allows a lower protein carrier/antigen ratio so the company can include more serotypes while minimizing carrier suppression. Vaxcyte recently reported impressive Phase 1/2 data for their VAX31 vaccine in adults. VAX31 looked at least as good as Pfizer’s standard of care PCV20 vaccine on the existing 20 serotypes (and was statistically superior on several serotypes) and added strong immune coverage of 11 additional serotypes. VAX31 now covers 95% of circulating strains in US adults and 98% in the EU. TheUSy will now run Phase 3 studies in adults and start a Phase 1/2 for VAX31 in children. We think that the pneumococcal vaccine market will be $10 billion-plus in 2030, that VAX31 can capture significant share, and that this will be a durable business.”
Overall, PCVX ranks 7th on our list of the best vaccine stocks to buy according to hedge funds. While we acknowledge the potential of PCVX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PCVX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article is originally published at Insider Monkey.
